Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 228

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 6
Chunk 228
---
 conditions of outstanding rights and rights  
           that may be granted in the future;                                                                                                        
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (d)      providing that participants’ accumulated payroll deductions                                                                             
           may be used to purchase shares prior to the next occurring purchase date on such date as the ESPP Administrator determines in its sole  
           discretion and the participants’ rights under the ongoing offering period(s) shall be terminated; and                                   
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (e)      providing that all outstanding rights shall terminate without  

Amendment; Termination.
The ESPP Administrator will have the authority to amend, suspend or terminate the ESPP. The ESPP is not subject to a specific termination
date.

  Board Practices  
 ───────────────────

Corporate Governance Practices

As an Israeli company, we
are subject to various corporate governance requirements under the Companies Law, relating to matters such as external directors, the
audit committee, the compensation committee and an internal auditor.

We are a “foreign private
issuer”, as such term is defined in Rule 405 under the Securities Act. As a foreign private issuer we will be permitted to comply
with Israeli corporate governance practices instead of the certain listing rules of Nasdaq, provided that we disclose which requirements
we are not following and the equivalent Israeli requirements.

We rely on this “foreign
private issuer exemption” with respect to the following:

  (i)      Quorum for Shareholder Meetings. Whereas under the corporate governance rules of Nasdaq, a quorum                                            

  (ii)      Shareholder approval. We do not intend to follow Nasdaq Stock Market rules which require shareholder                                         

  (iii)      Adoption or Amendment of Equity-Based Compensation Plan s. We have elected to follow Israeli corporate                                              

We otherwise intend to comply
with the rules generally applicable to U. S. domestic companies listed on the Nasdaq. We may, however, in the future decide to rely upon
the “foreign private issuer exemption” for purposes of opting out of some or all of the other Nasdaq listing rules.

For more information regarding
our corporate governance practices and foreign private issuer status, see Item 16G. “ Corporate Governance.”

Board of Directors

Under the Companies Law and
our Articles, our business and affairs are managed under the direction of our board of directors. Our board of directors may exercise
all powers